Skip to main content
. 2022 Feb 26;7(2):100409. doi: 10.1016/j.esmoop.2022.100409

Figure 4.

Figure 4

Currently active phase II and III trials for metastatic breast cancer (MBC) divided according to BC subtypes and drug categories (source:ClinicalTrials.gov; at 25 November 2021).

inh, inhibitor; mTOR, mammalian target of rapamycin; SERDs, selective estrogen receptor degraders, IMMUNO; immunotherapy; ADC, antibody drug conjugate; mAB, monoclonal antibody; TKI, tyrosine kinase inhibitor; PARP, poly-ADP-ribose polymerase; HR, hormone receptor.